How Sage Capital is making money from other investors’ panic
Joanne TranMarkets Reporter
Ozempic, the weight loss wonder drug that took the world by storm last year, prompted many hedge fund managers to ramp up bets that ResMed’s shares were heading for a cliff.
Veteran short seller Sean Fenton took the opposite approach and bought more shares in late 2023. His bet paid off – so far this year, the ASX-listed medical technology firm has soared more than 30 per cent.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Equity markets
Fetching latest articles